<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01588145</url>
  </required_header>
  <id_info>
    <org_study_id>HM-EMSI-101</org_study_id>
    <nct_id>NCT01588145</nct_id>
  </id_info>
  <brief_title>Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients</brief_title>
  <official_title>Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of HM61713 in NSCLC Patients With EGFR Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the safety and tolerability of HM61713.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Besides the main objective, there are 3 other objectives as follows:&#xD;
&#xD;
        -  To evaluate the anti-cancer effect of HM61713 in NSCLC patients with EGFR mutation&#xD;
&#xD;
        -  To investigate the pharmacokinetic profile of HM61713 and its metabolites after oral&#xD;
           administration&#xD;
&#xD;
        -  To investigate biomarkers related to the safety and efficacy of HM61713&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Dose limiting Toxicity will be evaluated on Day 24 during Cycle 1</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">273</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>HM61713</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM61713</intervention_name>
    <description>BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops</description>
    <arm_group_label>HM61713</arm_group_label>
    <other_name>Olmutinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically or cytologically confirmed diagnosis of advanced NSCLC&#xD;
&#xD;
          -  Patients with EGFR mutation-positive tumor&#xD;
&#xD;
          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of&#xD;
             2 or less&#xD;
&#xD;
          -  Estimated life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Subjects with adequate bone marrow (WBC ≥4,000/mm3, Platelet ≥100,000/mm3,&#xD;
             Hemoglobin≥9.0g/dL, ANC≥1,500/mm3), renal (Creatinine≤1.5 mg/dl) and hepatic&#xD;
             [aspartate aminotransferase (AST)/ alanine aminotransferase (ALT)/ alkaline&#xD;
             phosphatase (ALP)≤3 x ULN, Total bilirubin ≤2.0 mg/dL] function. No significant heart&#xD;
             and lung disease.&#xD;
&#xD;
             ※ For subjects with a liver metastases, AST/ALT/ALP≤ 5 x ULN is allowed; and for&#xD;
             subjects with bone marrow metastases, ALP≤ 5 x ULN is allowed&#xD;
&#xD;
          -  Patients with amylase level ≤ 1.5 x ULN&#xD;
&#xD;
          -  Subjects who have provided voluntary consent to participate in the study, and signed&#xD;
             the written consent document&#xD;
&#xD;
        &lt;Dose escalation part&gt;&#xD;
&#xD;
        - Malignancy that has progressed after at least two prior chemotherapy regimens, including&#xD;
        EGFR-TKI&#xD;
&#xD;
        &lt;Expansion part 1&gt;&#xD;
&#xD;
          -  Patients with disease progression despite anticancer therapy with EGFR-TKI (e.g.,&#xD;
             erlotinib, gefitinib, neratinib, afatinib, dacomitinib)&#xD;
&#xD;
          -  Patients who have provided voluntary consent for collection of tumor tissue taken and&#xD;
             archived after the last anticancer therapy or collection of new tissue specimen and&#xD;
             signed the written consent document&#xD;
&#xD;
        &lt;Expansion part 2&gt; &amp; &lt;Phase 2&gt;&#xD;
&#xD;
          -  Patients with disease progression despite anticancer therapy with EGFR TKI (e.g.,&#xD;
             erlotinib, gefitinib, neratinib, afatinib, dacomitinib) (Except treatment with EGFR&#xD;
             mutation selective inhibitor, the same class of drug as investigational drug in this&#xD;
             study)&#xD;
&#xD;
          -  T790M mutation-positive confirmed in tissue collected after PD is confirmed during or&#xD;
             after the last anticancer therapy&#xD;
&#xD;
          -  At least one measurable target lesion allowing repeated measurement according to&#xD;
             RECIST ver1.1 as of screening&#xD;
&#xD;
        &lt;Phase 1 Expansion part 3&gt;&#xD;
&#xD;
          -  Patients with disease progression despite anticancer therapy with EGFR TKI (e.g.,&#xD;
             erlotinib, gefitinib, neratinib, afatinib, dacomitinib) (Except treatment with EGFR&#xD;
             mutation selective inhibitor, the same class of drug as investigational drug in this&#xD;
             study)&#xD;
&#xD;
          -  T790M mutation-negative confirmed in tissue collected after progressive disease (PD)&#xD;
             is confirmed during or after the last anticancer therapy&#xD;
&#xD;
          -  At least one measurable target lesion allowing repeated measurement according to&#xD;
             RECIST ver1.1 as of screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hematologic malignancies&#xD;
&#xD;
          -  Symptomatic or uncontrolled central nervous system metastases&#xD;
&#xD;
          -  Interstitial lung disease, including pulmonary fibrosis&#xD;
&#xD;
          -  LVEF &lt; 40% or NYHA Class III or IV heart failure&#xD;
&#xD;
          -  History of pancreatitis&#xD;
&#xD;
          -  History or current evidence, of any psychiatric or congenital disorder, including&#xD;
             dementia or epilepsy&#xD;
&#xD;
          -  Compromised organ function, infection or allergy&#xD;
&#xD;
          -  Pregnant or breast-feeding women, or women of child-bearing potential who do not use&#xD;
             an appropriate method of contraception (male patients should also use an appropriate&#xD;
             method of contraception during the study period)&#xD;
&#xD;
          -  Patients who had received other investigational product within 30 days prior to&#xD;
             screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong-Wan Kim, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>April 26, 2012</study_first_submitted>
  <study_first_submitted_qc>April 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2012</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>HM61713</keyword>
  <keyword>EGFR-TKI</keyword>
  <keyword>Phase II</keyword>
  <keyword>olmutinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

